PharmaFocus Today – Page 4 – media

Huadong Medicine Discloses Positive Top-line Results for Weight-loss Drug, Pipeline May Be Revalued

Huadong Medicine announced that its wholly-owned subsidiary Sino-American East China has achieved positive top-line results in the China Phase III trial (HDM1002-301) of its Class 1 innovative oral small-molecule GLP-1 receptor agonist HDM1002 tablets for weight management in overweight or obese individuals. All dosage groups met all primary and key secondary endpoints at week 44; continued treatment resulted in sustained weight loss further decreasing at week 52 without a plateau; significant improvements in cardiometabolic markers, substantial reduction in liver fat content, and optimized body composition were observed; safety and tolerability were consistent with the GLP-1 class with no new signals. The company has completed Pre-NDA communication and will soon submit a marketing application in China. Research institutions indicate the biopharmaceutical industry will benefit from upcoming policies, with related companies expected to see improved performance. Source: https://finance.eastmoney.com/a/202609283885024341.html
- Source: drugdu
- 115
- September 29, 2026
Core Product Velyso Granted Orphan Drug Designation in Japan

On September 28, Leads Biolabs-B (09887) announced that its core product Velyso® (opatidijumimab, a PD-L1/4-1BB bispecific antibody) has been granted orphan drug designation by the Japanese Ministry of Health, Labour and Welfare for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third orphan drug designation that Velyso® has received, following those from the U.S. Food and Drug Administration and the European Commission, marking a further expansion of its global regulatory recognition into major Asian markets. Source: https://finance.eastmoney.com/a/202609283885132814.html
- Source: drugdu
- 107
- September 29, 2026
What Are Buyers Looking For, and What Are Suppliers Focused On?

From September 16–18, CPHI & PMEC Shenzhen 2026 brought together pharmaceutical companies and industry professionals across APIs, excipients, finished formulations, pharmaceutical machinery, and other segments of the pharma value chain. The Drugdu.com team was on-site throughout the three-day event. We met familiar faces, connected with new companies across different sectors, talked with buyers looking for products and suppliers, and sat down with companies exploring new ways to expand their international business. After three days of conversations, one thing stood out: What matters is not simply how many people you meet at an exhibition, but what buyers and suppliers are actually looking for. Buyers Are Looking for More Than Products “Do you have suppliers for this product?” “Are there other Chinese manufacturers we can compare?” “Can we contact the manufacturer directly?” Many of our conversations with buyers started with a specific product. But finding the product is only the first step. ...
- Source: drugdu
- 185
- September 23, 2026
Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million

On September 16, Novartis announced the acquisition of biotechnology company Sironax for $125 million, gaining access to its proprietary blood-brain barrier (BBB) delivery platform technology. Sironax’s platform utilizes receptor-mediated transcytosis to efficiently deliver large molecule drugs (such as antibodies and gene therapies) into the central nervous system, addressing the longstanding challenge of large molecules being unable to cross the BBB. The technology platform is expected to significantly enhance Novartis’ drug development capabilities in central nervous system diseases, including Alzheimer’s disease, Parkinson’s disease, and neuro-oncology. This acquisition continues Novartis’ recent strategic investments in neuroscience and rare diseases. Blood-brain barrier delivery technology is considered a key enabling technology for next-generation CNS drug development. Source: https://tldrbio.tech/
- Source: drugdu
- 206
- September 17, 2026
IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance

On September 16, IASO Biotherapeutics announced that its investigational new drug application for IASO208, a CD20-targeting in vivo CAR-T product developed on its proprietary InTelliCAR platform, has received FDA clearance in the U.S. As the first lentiviral vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will directly proceed to a Phase Ib study based on Chinese investigator-initiated trial data, targeting relapsed/refractory B-cell non-Hodgkin lymphoma. In vivo CAR-T is a next-generation cell therapy technology that eliminates the need for ex vivo T cell engineering, instead delivering vectors directly in patients to generate CAR-T cells in vivo. This approach has the potential to dramatically reduce treatment costs and timelines, moving cell therapy toward “off-the-shelf.” The FDA clearance for IASO208 signifies that China is competing on par with the international community in the in vivo CAR-T space, further deepening IASO Biotherapeutics’ internationalization in cell therapy. Source: http://m.toutiao.com/group/7686078944797311529/
- Source: drugdu
- 180
- September 17, 2026
NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer

On September 17, Everest Medicines announced that CDE of the NMPA has accepted the marketing registration application for Velsipity (etrasimod arginine tablets) for the transfer of manufacturing from overseas to domestic production, and has granted Priority Review. Local production is expected to commence in 2027. Velsipity was approved by NMPA in February 2026 for adult patients with moderate to severe active ulcerative colitis (UC) who have an inadequate response, loss of response, or intolerance to conventional therapies or biologics. Source: https://finance.eastmoney.com/a/202609173876680142.html
- Source: drugdu
- 199
- September 17, 2026
Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient.

On September 16, SSY Group announced that its ziprasidone mesylate has been approved by the NMPA of China for registration as an API used in marketed formulations. Ziprasidone mesylate is primarily used to treat acute agitation symptoms in patients with schizophrenia. According to the announcement, SSY Group has built a leading second-generation antipsychotic HPAPI platform in China, covering blonanserin, lurasidone, ziprasidone hydrochloride, and the newly approved ziprasidone mesylate. Source: https://finance.eastmoney.com/a/202609163876154835.html
- Source: drugdu
- 128
- September 17, 2026
Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association.

The 21st Chinese Pharmaceutical Association Science and Technology Award was presented at the 2026 Chinese Pharmaceutical Congress. The project “New Drug Creation and Industrial Innovation for Antidepressants Combining Traditional Chinese Medicine Syndromes,” in which Kanghong Pharmaceutical played a significant role, won the first prize. The Chinese Pharmaceutical Association Science and Technology Award was officially approved by the Ministry of Science and Technology in July 2005. It is sponsored by the Chinese Pharmaceutical Association and recognizes researchers and innovative achievements that have made major breakthroughs in pharmaceutical science. It is a highly prestigious and influential award in the domestic pharmaceutical field. Kanghong Pharmaceutical’s Shugan Jieyu Capsules are the core landmark achievement of this award-winning project. As the first approved traditional Chinese medicine for mild to moderate depression in China, this product is a Class II protected TCM variety and was recently included in the National Essential Medicines List (2026 Edition). Since ...
- Source: drugdu
- 163
- September 17, 2026
Johnson & Johnson celebrates the launch of Rybrevant FASPRO (amivantamab subcutaneous injection) in China

As China’s first and currently only approved subcutaneous injection formulation for the treatment of EGFR-mutant advanced non-small cell lung cancer, Rybrevant FASPRO reduces the administration time from several hours with traditional intravenous infusion to just minutes, and significantly reduces the risk of infusion-related adverse reactions. Johnson & Johnson today announced the official launch of Rybrevant FASPRO (amivantamab injection, subcutaneous) in China, in combination with LECLIZE (lazertinib mesylate tablets) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R substitution mutation. Rybrevant FASPRO is the first and currently only subcutaneous injection formulation approved in China for the treatment of patients with EGFR-mutant advanced NSCLC. Combined with lazertinib, it demonstrates significant ease of administration in first-line combination therapy, reducing administration time from several hours to just minutes. In terms of safety, compared with the intravenous formulation, Rybrevant ...
- Source: drugdu
- 146
- September 17, 2026
First! Novartis’ blockbuster generic radiopharmaceutical receives approval

On September 14, Curium announced that Bexlutry ([177lu]oxooctreotide, development code: PNT2003) had received FDA approval. This drug is Lutathera ([177lu]oxooctreotide), i.e., a generic version. This is the world’s first approved generic radiopharmaceutical. The original drug, Lutathera, is a radioligand therapy (RLT) targeting the somatostatin receptor type 2 (SSTR2), acquired by Novartis through its acquisition of Advanced Accelerator Applications. It was first approved for marketing in the European Union in 2017. Currently, the drug is indicated for adult patients and children aged 12 years and older with unresectable or metastatic, progressive, well-differentiated (G1 and G2) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET). According to Novartis’ financial report, Lutathera’s global sales were $816 million in 2025. In November 2022, Lantheus acquired exclusive global rights to PNT2003 from POINT Biopharma, excluding China, Japan, South Korea, Indonesia, and Singapore. In October 2023, Eli Lilly acquired POINT Biopharma for $1.4 billion, gaining the remaining rights to the ...
- Source: drugdu
- 151
- September 17, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.